Objective: A new head and neck cancer cell line was developed from a highly aggressive HNSCC of the oral cavity diagnosed in a 26-year-old pregnant woman. Methods: Cells from the primary tumor were passaged in culture and genotyped as a unique cell line. The resultant cell line was assessed for its ability to replicate the primary tumor. Results: The primary tumor and cell line contained 19.03% and 19.62% CD44 high cells, respectively. CD44 high cancer stem cells from UM-SCC-103 formed tumors after flank injections in mice that reconstituted the heterogeneity of the primary tumor. CD44 staining and histology in the primary tumor and tumors grown in vivo from the cell line were similar. CD44 high cells from the primary tumor resulted in lung colony formation in 2 out of 2 tail vein injections in mice, whereas CD44 low cells did not. Similarly, CD44 high cells from UM-SCC-103 formed lung tumors in 2 out of 4 mice, whereas CD44 low cells did not. Conclusion: The similarity in marker expression and tumorigenic behavior between the primary tumor and the resulting cell line strongly suggests that the cell line resembles the primary tumor that it was derived from and provides an important new research tool for the study of head and neck carcinomas in young patients.
Background
Established cell lines are as diverse as the head and neck squamous cell carcinoma (HNSCC) primary tumors from which they are derived. Acquiring a broad array of immortalized cell lines for research purposes is vital to study the variety of characteristics and behaviors of the tumors that these cell lines represent. The advantage of a replenishable supply of laboratory-cultivated cells for applications is especially important when samples from primary tumors are limited. The selective pressure of establishing a new cell line in vitro and the concern regarding whether it recapitulates the primary tumor have been noted. [1] [2] [3] Such concern is partially alleviated by the use of xenografts in animal models. 4, 5 Direct comparisons between cells from the primary tumor and the cell line later established from the primary tumor in regard to biomarker expression and tumorigenic potential may aid in confirming the similarities between the 2 cell populations.
Tumorigenicity in cell lines has been described as the process by which neoplastic cells growing in tissue culture form tumors when inoculated into an animal. 6, 7 Multiple xenograft models exist that provide for the observation of the tumorigenicity of a cancer cell line. 8 Subcutaneous injections along the flanks of an immunosuppressed animal can be used to demonstrate the potential of the cells to propagate in vivo. 9 Similarly, tail vein injection of a cell suspension can result in lung colonization if a tumorigenic cell population is used. [10] [11] [12] Lung colonization can be monitored over time by prior transduction of the cell line with a bioluminescent marker. 13 Cancer stem cells (CSC) are a subpopulation of cells that are highly tumorigenic, possess the capability to self-renew, and have the capacity to recreate the initial tumor heterogeneity. 6 Cancer stem cells have been isolated before in HNSCC using the markers cluster of differentiation 44 (CD44) and aldehyde dehydrogenase (ALDH). 14, 15 CD44 is a transmembrane surface adhesion molecule containing a ligand-binding region for hyaluronan, whose signaling has been linked to tumor progression, invasion, and metastasis in solid tumors, including HNSCC. 16, 17 Our lab has also shown that a compartment of CSC exists in HNSCC that has an increase of ALDH activity and is able to propagate in vivo when compared to cells with low ALDH activity. 15 Identification of the CSC compartment in primary tumors and cell lines is a necessary precursor to development of targeted therapy(ies) that could be applied against this subpopulation in conjunction with more traditional cancer treatments. We describe a tumor that arose in the tongue of a pregnant woman that was highly aggressive and spread, leading to distant metastasis. Head and neck squamous cancers are extremely rare in women and even more uncommon in pregnant women. This cell line provides a unique model to better understand the biological behavior of a rare aggressive tongue cancer arising in a young pregnant woman. The tumorigenicity of the primary tumor, as well as the resulting cell line established from it, can be attributed to the presence of an identifiable cancer stem cell population.
Methods
Approvals for the collection of cancer specimens and for use of the animal model were obtained through the appropriate review boards. The National Institutes of Health's Guide for the Care and Use of Laboratory Animals was followed.
Establishment of the Cell Line
Primary tumor tissue was transported from the operating room to the lab and was washed extensively in Earle's balanced salt solution containing penicillin, streptomycin, and amphotericin B. The tissue was then minced by scalpel blade and placed in culture flasks and covered with complete Dulbecco's Modified Eagle Medium (DMEM; Gibco, Grand Island, New York, USA) containing 10% fetal bovine serum, L-glutamine, penicillin, and streptomycin; 0.05% Trypsin-EDTA was used for partial trypsinization to aid in fibroblast removal. When sufficient outgrowth of epithelial cells was observed, tumor cells were detached using 0.125% trypsin and plated into new culture flasks. Supernatants were tested for mycoplasma using Myco Alert Mycoplasma Testing Kit (Lonza, Basel, Switzerland).
Tumor Digestion
Tumor tissue from the primary tumor, designated HN-111, and all xenografts were minced and digested in DMEM/F12 (Gibco) with 1X collagenase/hyaluronidase (Stem Cell Technologies, Vancouver, Canada). After 2 hours of digestion, the mixtures were strained through a 40-µm sieve and the cells were counted before being prepared for flow cytometry.
Immunohistochemistry UM-SCC-103 cells were cultured on chamber slides until 70% confluent, at which point they were fixed and permeabilized with 4% paraformaldehyde and 0.1% Triton-x (Sigma, St Louis, Missouri, USA). Tissue slides from the surgical specimen and from the murine xenografts were deparaffinized, rehydrated, and peroxidase-quenched (DakoCytomation, Glostrup, Denmark). All slides were incubated in antigen retrieval solution (DakoCytomation) for 40 minutes in 92°C water bath with a buffer change midway and allowed to cool to room temperature for 20 minutes. Horse serum was used for blocking (30 minutes at room temperature). Primary antibody anti-CD44 (BD Pharmingen, Franklin Lakes, New Jersey, USA) was added and allowed to incubate overnight at 4°C. Slides were washed, and secondary antibodies linked to avidin/biotin peroxidase (ABC Kit; Vector Laboratories, Burlingame, California, USA) were used to detect primary antibody binding.
RNA Extraction, Reverse Transcription Polymerase Chain Reaction, Gene Expression
RNA from UM-SCC-103 was isolated by an RNA mini kit (Qiagen, Venlo, Netherlands). cDNA was synthesized using the Reverse Transcription System Kit (Promega, Madison, Wisconsin, USA) according to the manufacturer's protocol, and detection of Bmi-1 was done using the forward primer 5'-aggccaacagcccagcagga-3' and the reverse primer 5'-actgcactggagtactggggc-3'.
Luciferase Transduction
UM-SCC-103 was transduced with human immunodeficiency virus (HIV) with a luciferase reporter, a lentiviral vector containing a pLentiLox backbone, and a cytomegalovirus promoter. Polybrene was added to increase efficiency of the transduction. Successful gene delivery was confirmed via green fluorescent protein (GFP) visualization in a side-by-side transduction of the HIV-GFP vector under identical conditions.
Flow Cytometry
CD44 expression was detected using an allophycocyanin (APC)-conjugated mouse antibody (BD Pharmingen). Cells were suspended in Hank's balanced salt solution (HBSS; Gibco) with 2% heat inactivated calf serum (HICS) added to a concentration of 1 million cells per mL. Five µL of antibody was added per mL of cell suspension and left to incubate on ice for 20 minutes. An APC-conjugated IgG2b isotype control antibody was used under the same conditions (BD Pharmingen). Aldehyde dehydrogenase expression was detected using the ALDEFLUOR kit (StemCell Technologies). Cells from UM-SCC-103 were brought to single cell suspension in ALDEFLUOR assay buffer (AAB) and incubated with ALDH substrate (BAAA, 5 mol/L per 1 × 10 6 cells) for 45 minutes at 37°C. Concurrently, diethylaminobenzaldehyde (DEAB 50 mmol/L) was added to a separate sample also containing BAAA for an ALDHinhibited control. Samples were washed and resuspended in AAB.
4',6-diamidino-2-phenylindole (DAPI; BD Pharmingen) was used as a cell viability indicator. Fluorescence-activated cell sorting gates were established using the inhibited control (DEAB) along the fluorescein isothiocyanate (FITC) channel with excitation and emission wavelengths of approximately 495 nm/521 nm. For CD44 expression, cell sorting gates were established using the APC-conjugated isotype control along the APC channel with excitation and emission wavelengths of approximately 650 nm/660 nm.
Flank Injections
CD44 high /ALDH high and CD44 low /ALDH low fractions from UM-SCC-103 were collected into separate tubes and 30 000 cells from each fraction were suspended in a mixture of 100 µL of DMEM and 100 µL of Matrigel extracellular matrix (BD Biosciences, San Jose, California, USA). The resulting 200 µL volumes were injected subcutaneously into opposite flanks of NOD/SCID mice (Jackson Laboratories, Bar Harbor, Maine, USA). Tumor growth from the CD44 high /ALDH high injection was allowed to persist for 12 weeks until harvested for sectioning and digestion. CD44 high and CD44 low fractions from UM-SCC-103-Luc were collected into separate tubes and 10 000 cells from each fraction were injected into both flanks of NOD/SCID mice. Each mouse was injected with either the CD44 high fraction in both flanks or the CD44 low fraction in both flanks and imaged at 4-week intervals.
Tail Vein Injections
CD44 high and CD44 low fractions from UM-SCC-103-Luc were collected into separate tubes, and cells from each fraction were suspended in 200 µL of phosphate-buffered saline (PBS; Gibco). The suspensions were injected into the tail veins of restrained NOD/SCID mice and imaged at 4-week intervals.
Bioluminescence Imaging
All animals treated with UM-SCC-103-Luc injections were imaged with the Xenogen IVIS-200 imaging system. Treated mice were given intraperitoneal injections of 100 µL luciferin at a concentration of 40 mg/mL and allowed to sit for 10 minutes before being anesthetized with isofluorane and imaged.
Results and Discussion

Case Report
A 26-year-old woman presented with a growing painful lesion of the right lateral oral tongue. Evaluation revealed a moderately differentiated T4N2b squamous cell cancer of the oral tongue. She had a remote 6-pack/year history of smoking but no other risk factors. Notably, she had recently become pregnant. She chose to undergo elective termination of her pregnancy. Surgical resection including hemiglossectomy, bilateral neck dissections, and a forearm free tissue reconstruction was performed. Due to the presence of multiple metastatic lymph nodes, several with extracapsular spread and extensive perineural invasion at the primary tumor site, she elected to undergo radiation with chemotherapy postoperatively. After initially receiving 3 doses of taxol/platinum-based chemotherapy and 5.4 gray of radiotherapy, she was unable to come to her appointments and was lost to follow-up. She presented about 6 months later with a large neck abscess that was proven to represent recurrent cancer that was found to be unresectable due to the extent of the neck disease. She completed a course of chemotherapy and radiation but developed distant metastasis and eventually succumbed to her disease.
Primary Tumor
The primary tumor had a CD44 high fraction consisting of 19.03% of the viable cancer cell population (Figure 1) . These CD44 high cells developed lung colonies in 2 out of 2 tail vein injections and a large abdominal tumor in 1 mouse (Table 1 ). There were no growths resulting from CD44 low injections. Histology and CD44 staining were similar between the primary tumor and the abdominal tumor resulting from the CD44 high injection (Figure 2) . It was not possible to evaluate the primary tumor for ALDH expression due to the small amount of tissue available for analysis.
UM-SCC-103
Pieces of the primary tumor were grown in culture and established as UM-SCC-103 ( Figure 3) . At passage 23, UM-SCC-103 had a CD44 high fraction of 19.62% and an ALDH high fraction of 3.17% (Figure 4 ). CD44 high / ALDH high cells grew flank tumors in 2 out of 2 mice, whereas CD44 low /ALDH low cells failed to form tumors in the flank ( Figure 5 ). The flank tumor derived from the CD44 high /ALDH high injection resembled UM-SCC-103 in CD44 staining and ALDH activity, with 4.12% of the population of viable cells from the tumor being ALDH high ( Figure 6 ). CD44 low cells exhibited lower Bmi-1 transcript expression than either unsorted control or CD44 high cells ( Figure 7A ). ALDH high cells had a 2.84-fold higher Bmi-1 transcript expression over ALDH low cells, relative to β-actin ( Figure 7B ).
UM-SCC-103-Luc
Cells transduced with luciferase grew lung tumors in 2 out of 4 mice receiving CD44 high tail vein injections and 0 out of 4 mice receiving CD44 low injections in the tail vein. One each of 2 mice developed lung tumors at cell concentrations of 100 000 and 50 000 ( Figure 8 ). The mouse with a lung tumor after 50 000 CD44 high cells was confirmed to have tumor by histology (Figure 9 ). Flank tumors developed in 4 out of 4 injection sites with CD44 high /ALDH high cells and only 2 out of 4 injection sites with CD44 low /ALDH low cells (Figure 10 ). The intensity of bioluminescence observed from the CD44 high /ALDH high flank tumors also exceeded that of the CD44 low /ALDH low flank growths by nearly 10-fold as measured by total flux (p/s) or average radiance (p/s/cm 2 /sr) ( Figure 11 ; Table 2 ). 
Conclusion
Cell lines have been critically important to investigators studying head and neck cancer and other malignant tumors. The development of a head and neck cell line from a piece of primary tumor is difficult and occurs with an efficiency of about 25%, requires a high degree of experience, and is very time and labor intensive. [18] [19] [20] Despite these difficulties, it is vital that we continue to develop new cell lines that represent the variety of primary cancers that occur in patients. UM-SCC-103 represents a unique cell line that was derived from a tongue cancer that developed in a young woman who was pregnant at the time her cancer was diagnosed. Analysis of the resultant cancer cell line reveals that the cell line shares features with the primary tumor, suggesting that it closely resembles the primary tumor. The tumorigenic stem cell population that exists in the primary tumor is conserved during its immortalization and can be identified with the same stem cell markers. The percentage of CD44 high cells remains relatively unchanged from primary tumor to cell line after more than 20 passages. Aldehyde dehydrogenase activity could not be measured in the primary tumor, but the stem cell population composed of ALDH high cells remains similar in cultured cells when compared to a xenograft tumor grown from the stem cell population. The sorted ALDH high cells are capable of reconstituting the original tumor heterogeneity, fulfilling a condition required of a cancer stem cell. 6, [21] [22] [23] [24] Similarly, in vivo tumorigenicity of the stem cell population in the cell line was also comparable to that of the primary tumor. CD44 high cells sorted from the primary tumor were able to grow nodules in the lungs of mice, which is also where CD44 high cells from the luciferase-transduced cell line were seen. In both the cell line and the cells sorted from the primary tumor, the CD44 low injections failed to grow tumors. The targeting of the lung epithelium by CD44 has been reported in other cancers as a potential marker of metastasis. [25] [26] [27] [28] [29] CD44 high cells that were also ALDH high grew tumors in each attempted flank injection. These tumors also grew more quickly and were larger than the tumors from CD44 low /ALDH high injections as measured through bioluminescence of the luciferase-transduced cell line. It is unknown whether those tumors arose from a sorting error or whether they propagated from a CD44 low /ALDH low cancer stem cell. Current literature suggests the possibility of the cancer stem cell to move between different phenotypes, and this may be reflected in the expression of stem cell markers such as CD44 and ALDH. 30, 31 Evaluation of Bmi-1 expression, a gene shown to be expressed in stem cells, 32,33 reveals a higher expression in the putative CSC population sorted from the cell line. This was observed in both the CD44 high and ALDH high populations when compared with their respective low populations. Further research is warranted into how the CD44 high / ALDH high population compares in gene expression and whether using both stem cell markers will narrow down the active stem cell population rather than using a single marker.
Although cell lines should not be viewed as a perfect mirror of the tumor, as it existed in the patient, this cell line does reflect the same tumorigenic behavior in vivo and should be regarded as a valuable tool to study the role of cancer stem cells in HNSCC progression. The patient had a stormy course with rapid progression. Her tumor also had a remarkably high stem cell population as measured by a CD44 high population. It is not possible to determine whether this high fraction of cells with a cancer stem cell phenotype was responsible for the aggressive course of her tumor progression since she also had interruptions in her treatment, which is also associated with poor response to treatment and tumor progression. Further complicating treatment was the pregnancy status of the patient. Although still uncommon, cancer during pregnancy is beginning to occur more frequently as women delay having children until they are older. The effects of pregnancy hormones are still unknown in head and neck cancer, but estrogen and progesterone have been linked to causing and fueling growth in breast, ovarian, endometrial, and colorectal cancers. [34] [35] [36] This cell line provides a unique research opportunity as being derived during a pregnancy. UM-SCC-103 is available for other investigators to study.
